Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909149 | 0.82 | METAP2 (0.55) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL12349895 | 0.81 | METAP2 (0.58) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL28461774 | 0.81 | METAP2 (0.53) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL13737550 | 0.78 | METAP2 (0.50) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL13738005 | 0.77 | METAP2 (0.49) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL19631302 | 0.77 | METAP2 (0.49) | METAP2CCR1RAB9ACCR5PARP1 | |
| SCHEMBL28892601 | 0.77 | MTNR1A (0.56) | RAB9AMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL30003079 | 0.77 | MTNR1A (0.56) | RAB9AMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL30843784 | 0.75 | TERT (0.46) | CCR1MEN1KMT2ACYP1A2 | |
| SCHEMBL1567897 | 0.75 | TERT (0.46) | CCR1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-10800766-B2 | Quinoline alkenes as cytoprotective agents | NEURODON CORPORATION | 2020-10-13 | — | — | US | disclosed |
| US-10383867-B2 | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders | NEURODON CORPORATION | 2019-08-20 | — | — | US | disclosed |
| US-20170151225-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS | NEURODON CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170151225-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS | NEURODON CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170151225-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS | NEURODON CORPORATION | 2017-06-01 | — | — | US | disclosed |
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2678329-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012154274-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383867-B2 | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders | ATP2A1, ATP2A3, ATP2A2 | METAP2 3553/4885CCR1 4636/4885RAB9A 559/4885 |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | METAP2 3197/4885CCR1 3163/4885RAB9A 3116/4885 |
| US-10800766-B2 | Quinoline alkenes as cytoprotective agents | IAPP, NFE2L2, KEAP1 | METAP2 3543/4885CCR1 3000/4885RAB9A 2381/4885 |
| US-20170151225-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND DISORDERS | ATP2A1, ATP2A3, ATP2A2 | METAP2 3553/4885CCR1 4636/4885RAB9A 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.